Charles Russell Speechlys advises SAI MedPartners on its acquisition of IDEA Pharma
We have advised SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology and medical device industries, on its acquisition of IDEA Pharma (“IDEA”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022.
SAI is a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Reading, Pennsylvania in the USA, SAI provides best-in-class competitive intelligence and strategy support services to assist its clients across the product development lifecycle. SAI works with leading multinational pharmaceutical companies, in addition to a growing number of biotechnology and medical device companies, and has a presence across the United States, Europe, and Asia.
IDEA, headquartered in London, United Kingdom and with employees across Europe and the United States, specialises in pharmaceutical path-to-market strategy and innovation. Its expertise in early-phase positioning, clinical development and commercialisation, when integrated with SAI’s extensive knowledge and expertise in competitive intelligence, market research and market access consulting services, will create a unique value proposition for biopharma clients
Based in Bethesda, Maryland in the USA, NCP is a middle market private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested $1.7 billion of equity capital.
Daniel Rosenberg, Corporate Partner, commented:
“We were delighted to work with this US private equity backed-client on an important transaction that will strengthen SAI’s capacity to offer comprehensive strategic services to its biopharma clients, supporting the process from drug discovery to market launch and lifecycle management.”
The Charles Russell Speechlys team was led by Daniel Rosenberg and included Caroline Carter, Nathan Lightman, Laura Crotch, Amy Farrer, Cheryl Tham and Anet Babychan (Corporate), Caroline Young, Dillon Ravikumar and Victor Mound (Commercial/IP/IT), Emily Chalkley, Isobel Goodman and Lucy Lintott (Employment) and Robert Birchall, Tess Newman and Tim Edgar (Tax). Charles Russell Speechlys worked alongside Bass Berry & Sims, who represented SAI on the US aspects of the transaction.
